Recursion Pharmaceuticals (RXRX) is up 12.9%, or 54c to $4.74.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Unusually active option classes on open December 17th
- Recursion Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
- Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating
- Cautious Hold Rating on Recursion Pharmaceuticals Amid Promising REC-4881 Data and Safety Concerns
- Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals